Currently, threeFDA-approved drugs (donepezil, galantamine, andrivastigmine) that are based on the “one drug–one target”strategy treat symptoms by inhibiting AChE, demonstrating the shortcomingsof this approach for the complex nature of AD. This evidence concerns the gene ACHE and Alzheimer disease.